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RESUMEN
Se sintetizan derivados del sistema heterocíclico 3-(pirrol-
1-il)tieno[2,3-b]piridina 5 y 6 con diversos sustituyentes
en la posición 2. Algunos de estos productos se usan
para preparar diversos anillos heterocíclicos que con-
tienen nitrógeno u oxígeno en la posición mencionada.
Se investigan las configuraciones electrónicas de pro-
ductos seleccionados empleando el método de orbita-
les moleculares semiempírico AM1. Se observan varia-
ciones considerables en la magnitud i en la orientación
del momento dipolar. Además, se investiga la estabili-
dad relativa de las estructuras bajo condiciones fisioló-
gicas calculando el componente electrostático de la ener-
gía libre de solvatación. La serie sintetizada muestra
energías libres de solvatación favorables, dentro del mar-
gen de –30 a –23 kcal/mol. La alta polaridad y los cam-
bios favorables de energía libre de solvatación en con-
diciones fisiológicas sugieren que la sustitución en la
posición 2 podría incrementar la actividad biológica de
los derivados de 3-(pirrol-1-il)tieno[2,3-b]piridina. 
Palabras clave: Tienopiridinas. 1,3-Cetoenamina. Hidró-
lisis. Acoplamiento. AM1. Energía libre de solvatación.
Momento dipolar.
SUMMARY 
Derivatives of a heterocyclic system 3-(pyrrol-1-yl)thie-
no[2,3-b]pyridine 5 and 6 carrying various substituents
in the position 2 were synthesized. Some of these pro-
ducts were used to build up a variety of nitrogen- and/or
oxygen-containing heterocyclic rings in that position. The
electronic configurations of selected products were inves-
tigated using the AM1 semi-emperical molecular orbital
method. Considerable variations in the magnitude and
oriention of the dipole moment were observed. Further,
the relative stability of the structures was investigated at
physiological conditions via calculation of the electros-
tatic component of  the solvation free energy. The synt-
hesized series showed favourable solvation free ener-
gies which were within the range from –30 to –23 kcal/mol.
The high polarity and favourable solvation free energy
changes at physiological conditions suggest that subs-
titution in the position 2 could enhance the biological
activity of the 3-(pyrrol-1-yl)thieno[2,3-b]pyridine deriva-
tives. 
Key words: Thienopyridines. 1,3-Ketoenamine. Hydrolysis.
Coupling. AM1. Solvation free energy. Dipole moment. 
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RESUM 
Es sintetitzen derivats del sistema heterocíclic 3-(pirrol-
1-il)tieno[2,3-b]piridina 5 i 6 amb diversos substituents
a la posició 2. Alguns d’aquests productes s’empren per
a preparar diversos anells heterocíclics que contenen
nitrogen o oxigen en la posició esmentada. S’investiguen
les configuracions electròniques de productes selec-
cionats emprant el mètode d’orbitals moleculars semiem-
píric AM1. S’observen variacions considerables en la
magnitud i l’orientació del moment dipolar. A més, s’in-
vestiga l’estabilitat relativa de les estructures sota con-
dicions fisiològiques calculant el component electrostà-
tic de l’energia lliure de solvatació. La sèrie sintetitzada
mostra energies lliures de solvatació favorables, dins el
marge de –30 a –23 kcal/mol. L’alta polaritat i els canvis
favorables d’energia lliure de solvatació en condicions
fisiològiques suggereixen que la substitució en la posi-
ció 2 podria incrementar l’activitat biològica dels deri-
vats de 3-(pirrol-1-il)tieno[2,3-b]piridina. 
Mots clau: Tienopiridines. 1,3-Cetoenamina. Hidròlisi.
Acoblament. AM1. Energia lliure de solvatació. Moment
dipolar.
INTRODUCTION
In the last few years, 3-cyanopyridine-2-(1H)-thiones have
attracted great attention from many researchers due to
their unusual properties and possibilities for use as synt-
hons for preparing novel biologically active substan-
ces(1-4). For example, 4,6-diaryl-3-cyanopyridine-2-(1H)-
thiones are used for the synthesis of antioxidants, biocides,
dyes, and other practically valuable substances(5-7).
Additionally, a wide range of biological activities has been
attributed to thienopyridines. In particular, derivatives of
the thieno[2,3-b]pyridine nucleus have significant biologi-
cal importance. They show anti-bacterial(8, 9), anti-cancer(10),
and anti-inflammatory(11, 12) activities. Others have been repor-
ted to be used as lipoxygenases inhibitors(13). On the other
hand, pyrrole and its derivatives also constitute an impor-
tant family of compounds due to their applications as phar-
maceuticals, such as fungicides, antibiotics(14-17), nonste-
riodal anti-inflammatory drugs (NSAIDS)(18-20), cholesterol-
reducing drugs(21), and anti-tumor agents(22, 23). In conjunc-
tion with an ongoing program aimed at developing efficient
syntheses of functionally substituted heteroaromatics uti-
lizing readily obtainable inexpensive starting materials(24-26),
it seemed therefore relevant to design and synthesize a
series of novel 3-(pyrrol-1-yl)thieno[2,3-b]pyridine deriva-
tives as potential bioactive molecules. This approach was
also stimulated by the assumption that the introduction of
biologically active heterocycles in the 2-position of thie-
no[2,3-b]pyridine moiety may lead to compounds of gene-
ral and analytical biological significance.
RESULTS AND DISCUSSION
In our recent review(27), we presented the chemistry of α-
haloketones and their utility in heterocyclic synthesis. In
the present study, we have extended the utility of an appro-
priate α-haloketone, namely; chloroacetone, in the synt-
hesis of aminoketones 3a,b as new key precursors for this
study. Thus, S-alkylation of pyridinethione derivative 1a(28, 29)
(Ar = C6H4Cl-p) with chloroacetone was carried out in the
presence of alkali. S-Acetylmethylthiopyridine 2 was the
product from reaction of an equimolar ratio of 1a, chloro-
acetone, and potassium hydroxide. When compound 2 was
heated in dimethylformamide (DMF) in the presence of alka-
li (Thorpe-Ziegler conditions), it cyclized into the corres-
ponding 2-acetyl-3-aminothienopyridine 3a. Alternatively,
compound 3a may also be obtained in one step from the
same starting materials without isolation of the interme-
diate product by using a two-fold excess of potassium
hydroxide. Better yield of the required product was obtai-
ned in this case. Likewise, it has been found that pyridi-
nethione derivative 1b(28, 29) (Ar = C6H4OMe-p) could react
with chloroacetone, in DMF in the presence of excess potas-
sium hydroxide, to afford the bicyclic product 3b. Obviously,
this reaction occurred, in this case, through the interme-
diacy of 2b (Scheme 1). The thieno[2,3-b]pyridine structu-
re 3 was suggested for those reaction products on the
bases of their molecular formulae and on their spectral
data. Compound 3a, as a representative example, indica-
ted in its IR spectrum the disappearance of the absorption
band characteristic for cyano group and the presence of
two absorption bands due to symmetric and asymmetric
stretching frequencies of primary amine at 3415 and 3275
cm–1 and another band at 1645 cm–1 corresponding to car-
bonyl group. Its 1H NMR spectrum exhibited a singlet inte-
grating for 3-protons at δ2.61 ppm attributable to acetyl
group, as well as a singlet integrating for 2-protons at δ8.20
ppm assigned to the NH2 group, besides the expected mul-
tiplet signal for the aromatic protons. Moreover, its 13C NMR
spectrum was also in accordance with the proposed struc-
ture (see Experimental section for details).
The reactivity of enaminoacetyl moiety in 3b was demons-
trated by its treatment with nitrous acid to produce a tricy-
clic product of molecular formula C28H19N5O2S (M/Z = 489)
which could be formulated as the thienopyridopyridazino-
ne derivative 4, according to elemental analysis and spec-
tral data. The IR spectrum of this product showed the pre-
sence of pyridazinone-CO (1704 cm–1) group while its 1H
NMR spectrum revealed the absence of NH2 signal and the
presence of a singlet signal for pyridazinone-CH2. In accor-
dance with literature(30), β-enaminocarbonyl compounds
3a,b were easily condensed with 2,5-dimethoxytetrahy-
drofuran, in boiling acetic acid, to give the respective pyrrolyl
ketones 5a,b (Scheme 1). The analytical and spectrosco-
pic (IR and NMR) data of the products 5a,b are consistent
with their structural assignments (see Experimental sec-
tion for details).
In spite of the rich chemistry with pyridinethiones(31-34), it is
surprisingly that there is no report, to the best of our know-
ledge, on the formation of enaminones using pyridinethio-
nes as starting materials. In this regards, the reactivity and
synthetic potentials of the acetyl derivative 5b for the for-
mation of an enaminone was explored by its interaction
with little excess (1:1.2 mole) of dimethylformamide dimethy-
lacetal (DMFDMA). This reaction led to the formation of a
bicyclic product of molecular formula C35H29N5O2S (M/Z =
583), whose structure was based on correct elemental
analysis and spectroscopic data studies. Thus, its IR spec-
trum revealed the presence of the absorption band cha-
racteristic for CO group at 1652 cm–1. Also, its 1H NMR spec-
trum exhibited, besides the expected signals, a singlet
signal at δ2.98 (6H) ppm due to the dimethylamino group
as well as two doublets at δ5.75 (1H) and δ8.40 (1H) ppm
with a J value of 14 Hz which can be only attributed to trans
olefinic protons. Furthermore, its 13C NMR spectrum was
also in agreement with the proposed structure. All these
data indicate that the reaction product could be formula-
ted as the 3-(dimethylamino)-1-(thieno[2,3-b]pyridinyl)pro-
penone structure 6. To our knowledge, this is the first repor-
ted formation of an β-enaminoketone from a pyridinethione.
The versatility of the 1,3-ketoenamine 6 was proved by
studying its reactivity towards each of nitrogen nucleop-
hiles and nitrogen electrophiles as well (Scheme 2 & 3).
Interestingly, this enaminone has been utilized as a star-
ting material for preparing the targeted isoxazole and pyra-
zole ring systems (Scheme 2). Thus, treatment of that β-
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Scheme 1
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Scheme 2
ketoenamine 6 with hydroxylamine hydrochloride, in the
presence of sodium acetate in ethanol, furnished a cyclic
product that may be formulated as 10a or 11a. In order to
establish the structure of that product, the acetyl derivati-
ve 5b was allowed to react with hydroxylamine hydroch-
loride and subsequent treatment of the formed oxime 12a
with DMFDMA. The product of this sequence of reactions
proved to be different from that of the reaction of 6 with
hydroxylamine hydrochloride. Thus, the isoxazole struc-
ture 10a could be established for that product. By analogy
with hydroxylamine, compound 6 also reacted with
phenylhydrazine to yield a product of addition and dimethy-
lamine elimination. Again, the pyrazole structure 10b was
established for that product based on the non-identity of
reaction of 6 with phenylhydrazine with a sample of 11b,
prepared via initial condensation of 5b with phenylhydra-
zine and subsequent reaction of the formed phenylhydra-
zone 12b with DMFDMA. The synthesis was expanded to
include the preparation of a new pyrazole derivative 10c
by reaction of compound 6 with hydrazine hydrate. It can
thus be stated that the reaction of 6 with hydroxylamine
hydrochloride, phenylhydrazine, or hydrazine hydrate pro-
ceeded by initial addition of the unsubstituted hydroxyla-
mine or hydrazine nitrogen to the activated double bond
of 6 to form the non-isolable acyclic adducts 7a-c follo-
wed by elimination of a dimethylamine molecule to give
the acyclic intermediates 8a-c. The latter underwent intra-
molecular condensation to yield the final products 10a-c,
respectively, whereas compounds 11a,b arose by the alter-
nate route, i.e. condensation of 12a,b with DMFDMA
(Scheme 2). Elucidation of the proposed structure of the
latter products was established on the basis of elemental
analyses and spectral background in each case. No absorp-
tion bands for CO groups in the IR spectra of 10a-c, indi-
cating the formation of a cyclic structure, in each case.
Additionally, their 1H NMR spectra revealed the complete
absence of dimethylamino group, while they revealed only
the presence of signals for methoxy, pyrrole-CH, isoxa-
zole-CH or pyrazole-CH and aromatic protons (see
Experimental section for details). The above reactions of
the 1,3-ketoenamine 6 with various nitrogen nucleophiles
open up a facile and convenient route to a variety of iso-
xazoles and pyrazoles, that are otherwise difficult to
access, and seem to be of interest as potential bioactive
molecules.  
The reactivity of the ketoenamine 6 towards some nitro-
gen electrophiles was also examined. It has been found
that incorporation of the cinnoline moiety into thienopyri-
dine structure was achieved by converting of the enami-
none 6 into its corresponding acyclic hydrazonal 14a follo-
wed by cyclization of the latter with sufuric acid. Thus,
typical for our recent reported behaviour of enamines
towards aromatic diazonium salts(26, 35), compound 6 was
coupled with an equimolar amount of p-tolyldiazonium
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chloride or its p-chloro analogue, yielding products of cou-
pling and hydrolysis of the dimethylamine moiety. Thus,
the acyclic β-ketoaldehyde structure 14 could be esta-
blished for those products based on their 1H NMR spec-
tra. In case of 14a, 1H NMR spectrum showed the appea-
rance of the formyl group at δ 10.02 ppm and the hydrazone
hydrogen proton at δ 14.20 ppm. Formation of 14a,b was
assumed to be formed by coupling at C-2’ of the α,β-unsa-
turated ketone 6 with diazonium ion followed by hydroly-
sis of the substituent at 3-position into the formyl group
by the action of the aqueous base existing in the medium.
p-Tolylhydrazone derivative 14a seemed to be a useful
candidate for further chemical transformations. Thus, it
further coupled with p-tolylbenzenediazonium chloride
salt, yielding the bisazo compound 16 via the intermediacy
of 15. The structure of the isolated formazan 16 was
further proved by an alternative synthesis. Thus, it could
be successfully obtained via an independent one step rou-
te involving the coupling of 6 with excess p-tolylbenze-
nediazonium chloride in DMF at 0-5 °C. Compound 16 pre-
pared by this route was found to be identical in all respects
(mp, mixed mp and IR data) to that prepared as descri-
bed before. Closure of the cinnoline ring was carried out
by condensation of the arylhydrazonal 14a with concen-
trated sulfuric acid to give, similar to our earlier report on
arylhydrazonals(35), the corresponding cinnoline derivative
18. A proposed mechanism for the formation of 18 invol-
ved a nucleophilic attack by the aromatic ring of the hydra-
zone moiety on the formyl carbonyl carbon, affording the
intermediate 17 followed by elimination of a water mole-
cule to give the final product 18 (Scheme 3). The analyti-
cal and spectral data obtained for 18 were in agreement
with the assigned structure. A Band of CO group appea-
red in its IR spectrum, while its 1H NMR spectrum confir-
med the presence of CH3 and OCH3 functions, in addition
of the aromatic protons, in their proper positions (see
Experimental section for details). This reaction represents
an easy access to 3-aroylcinnoline 18. Notably, a literatu-
re survey revealed that benzopyridazine analogues are
biologically interesting candidates(36), especially as anti-
bacterial(37) and anxiolytic(38) agents. Work along the expan-
sion of such synthetic approach is now in progress. A dis-
cussion of the biological results will be the subject of a
future publication.
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Conformational flexibility and relative stability
at physiological conditions
Due to the importance of the thieno[2,3-b]pyridines in terms
of their established biological activities, it’s been neces-
sary to understand quantitatively the effect of different
substituents on the electronic properties of the synthesi-
zed series. This has been investigated via calculation of
the electronic distribution of the structures using the AM1
level of theory(39, 40) (see Energetics). 
The molecular structure is by no means a still-life image.
The thienopyridine structure is a common moiety throug-
hout the series with a multitude of rotameric states due to
free rotation of the phenyl and the p-methoxyphenylazo
substituents. These single-bond rotations are interdepen-
dent and correlated due to the closeness and bulkiness of
the substituents and thereby the rotameric states of the two
phenyl rings are very much dependent on the rotameric sta-
te of the intervening p-methoxyphenylazo group. Therefore,
we decided to map the dihedral energy profile of the p-met-
hoxyphenylazo substituent for each member in the series
by incrementing the C1-C2-N=N dihedral in 10-degree steps
(Figure 1). The energy profiles indicate that the structures
span two minima that are less than 0.5 kcal/mol apart with
an energy barrier that is less than 2.5 kcal/mol. Therefore,
at room temperature, a state of equilibrium exists where the
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Figure 1. Energy profiles of the C-C-N=N dihedral rotation for the nine thieno[2,3-b]pyridine derivatives based on applying
constraints at incremental dihedral steps of 10 degrees and  relaxation of the free degrees of freedom by geometry opti-
mization using the AM1 semiemperical model.
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p-methoxyphenylazo group is equally likely to exist in two
rotameric states. Moreover, the low energy barriers betwe-
en the two minima indicate that intermediate states have
significant contribution to the equilibrium ensemble.
Importantly, the electronic properties of the ensemble of
the rotameric states does not span a significant range of
variation (data not shown); e.g. the direction of the dipole
moment lies within ± 10º from the most stable structure.
Therefore, we decided to focus only on the lowest energy;
i.e. the most stable conformer for each structure in the series.
It is interesting to note that a common feature of the lowest
energy structures is the stacking of the substituents in a
direction which is almost perpendicular to the thieno[2,3-
b]pyridine moiety (Figure 2). Such stacking confers stabi-
lity on the molecular structures whilst its degree is pri-
mordial for their relative stability. This is a reminiscent of
the role of base-pair stacking in DNA structures(41, 42). 
However, given that the biological system is the native envi-
ronment for in vivo studies of putative drug candidates, the
calculations have been supplemented by computation of
the solvation free energy (∆Gsolv) of each of the series mem-
bers via solving the Poisson-Boltzmann equation(43) at phy-
siological conditions (0.15 M NaCl and 310 K). Inspection
of Table I reveals that the whole series shows favourable
free energies of solvation that are within the range from
–30 to –23 kcal/mol with the 3b structure being the least
stabilized. It is quite evident thereby that substitution in
the 2-position enhances the stability of the thieno[2,3-b]pyri-
dine derivatives at physiological conditions. The trend in
stability due to solvation under these conditions is also clo-
sely matched by decrease in the magnitude of the dipole
moment whilst the 3b structure having the largest dipole
moment (Table I). Moreover, the variation in the magnitu-
de of the dipole moments is accompanied by noticeable
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Figure 2. Cross-eyed stereo view of the energy-minimized geometry of 11a-structure using the AM1. Hamiltonian at a res-
tricted Hartree-Fock (RHF) self-consistent field level. For the sake of clarity, hydrogen atoms are not shown. 
TABLE I
The conformational parameters and energetics of the lowest energy conformers of  thieno[2,3-b]pyridine derivatives. 
Dihedrals Dipole
Structure
∆Gsolv IP‡ HOMO-LUMO
C1-C2- MomentPh1 Ph2 [kcal/mol] [Hartree] gap [Hartree]
N=N [Debye]
11b 102.0 -117.8 85.6 -31.152 1.978 0.313 0.280
18 116.0 -117.4 92.4 -29.380 4.644 0.284 0.245
10c 98.2 -117.7 91.1 -28.340 4.773 0.317 0.276
10b 105.5 -116.7 75.9 -27.957 4.398 0.315 0.279
11a 105.8 -117.1 85.1 -26.725 5.017 0.320 0.279
5b 98.6 -116.3 73.4 -26.530 5.010 0.315 0.276
10a 99.5 -117.8 92.8 -25.634 5.500 0.323 0.274
4 104.9 -116.9 74.6 -25.325 3.909 0.323 0.271
3b 113.4 -117.1 99.3 -23.915 7.216 0.297 0.267
‡ IP: The Ionization Potential
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change in its direction (Figure 3) which indicates appre-
ciable redistribution of charge over the molecular skeleton
due to substitution. This could have drastic consequences
on the mode of binding of this series of structures to puta-
tive receptor sites, which is the subject of an ongoing study.
On the other hand, the ionisation potential and the HOMO-
LUMO energy gap do not show significant variation due to
substitution in the 2-position which implies a limited effect
of the current substitution scheme on charge transfer reac-
tions.
CONCLUSION
In conclusion, we have demonstrated the potential uses of
2-acetyl derivative 5b and enaminone 6 as new versatile
building blocks for the preparation of a variety of pharma-
ceutically important arylazo derivatives of 3-(pyrrol-1-yl)thie-
no[2,3-b]pyridine, for which we might expect a wide spec-
trum of bioresponses, especially as anti-bacterial and
anti-cancer agents. 
EXPERIMENTAL
Melting points are uncorrected. IR spectra were recorded
(KBr) on a Pye Unicam SP-1000 spectrophotometer. NMR
spectra were obtained on a Varian Gemini 300 MHz spec-
trometer in DMSO-d6 as solvent and TMS as internal refe-
rence. Chemical shifts are expressed in δ ppm. EI mass
spectra were recorded on a Finnigan MAT SSQ 710 at 70
eV. Compounds 1a,b were prepared following the publis-
hed procedure(28, 29).
Synthesis of 2-Acetylmethylthio-5-[(4-chlorophenyl)
diazenyl]-4,6-diphenyl-1,2-dihydropyridine-3-
carbonitrile (2)
Chloroacetone (0.005 mol) was added to a stirred sus-
pension of pyridinethione 1a (0.005 mol), in dimethylfor-
mamide (20 ml) in the presence of potassium hydroxide
(0.005 mol). The reaction mixture was kept for 2 h at room
temperature under stirring and then diluted with cold water
(~ 20 ml). The precipitate was filtered off, washed with
water, dried and recrystallized from EtOH to give the mer-
capto derivative 2 (0.75 g; 31%). Mp 120-122 ºC; IR (v/cm–1)
= 3055 (CH aromatic), 2226 (CN), 1710 (C=O ketone); 1H
NMR δH = 2.36 (s, 3H, COCH3), 6.03 (s, 2H, SCH2), 7.35-7.97
(m, 14H, 2C6H5, C6H4); C27H19ClN4OS (482.984): Calcd: C,
67.14; H, 3.97; Cl, 7.34; N, 11.60; S, 6.64; Found: C, 66.87;
H, 4.02; Cl, 7.12; N, 11.35; S, 6.40.
General Procedure for the Synthesis of 5-(Aryldiazenyl)-
2-acetyl-3-amino-4,6-diphenylthieno[2,3-b]pyridines 3a,b
Method (A) for compounds 3a,b
To a solution of either pyridinethione 1a or 1b (0.005 mol)
in dimethylformamide (25 ml), potassium hydroxide (0.01
mol) and chloroacetone (0.005 mol) were added. The reac-
tion mixture was refluxed with stirring for 1 h and then allo-
wed to stand at room temperature overnight under stirring.
The reaction mixture was then diluted with cold water and
the resulting precipitate, in each case, was removed by fil-
tration, dried and recrystallized from the proper solvents
to give the enaminoketones 3a (1.28 g; 53%) and 3b (1.34
g; 56%), respectively. 
2-Acetyl-3-amino-5-[(4-chlorophenyl)diazenyl]-4,6-
diphenylthieno[2,3-b]pyridine (3a)
Mp 211-213 ºC (DMF/H2O); IR (v/cm
–1) = 3415, 3275 (NH2),
3036 (CH aromatic), 1645 (C = O with H-bonding), 1614 (C=N);
1H NMR δH = 2.61 (s, 3H, COCH3), 7.41-7.89 (m, 14H, 2C6H5,
C6H4), 8.20 (s, br, 2H, NH2, D2O-exchangeable); 
13C NMR δC
= 27.3 (CH3), 122.8, 125.4, 126.1, 126.5, 127.0, 127.4, 128.1,
128.4, 128.9, 129.5, 130.4, 134.2, 137.9, 138.9, 142.5, 143.6,
144.8, 150.5, 158.1 (aromatic-C), 191.8 (C=O); C27H19ClN4OS
(482.984): Calcd: C, 67.14; H, 3.97; Cl, 7.34; N, 11.60; S, 6.64;
Found: C, 66.91; H, 3.73; Cl, 7.21; N, 11.47; S, 6.51.
2-Acetyl-3-amino-5-[(4-methoxyphenyl)diazenyl]-4,6-
diphenylthieno[2,3-b]pyridine (3b)
Mp 190-191 °C (1,4-dioxane); IR (ν/cm–1) = 3421, 3286 (NH2),
3040 (CH aromatic), 1645 (C=O with H-bonding), 1618 (C=N);
1H NMR δH = 2.49 (s, 3H, COCH3), 3.91 (s, 3H, OCH3), 7.11-
7.82 (m, 14H, 2C6H5, C6H4), 7.99 (s, br, 2H, NH2, D2O-exchan-
geable); MS: m/z (%) = 478 (M+, 17%); C28H22N4O2S (478.565):
Calcd: C, 70.27; H, 4.63; N, 11.71; S, 6.70; Found: C, 70.03;
H, 4.48; N, 11.47; S, 6.61.
Method (B) for compound 3a
Potassium hydroxide (0.005 mol) was added to compound
2 (0.005 mol) in dimethylformamide (20-25 ml), the mixtu-
re was refluxed with stirring for 30 min and then diluted
with cold water (~ 20 ml). The precipitate formed was fil-
tered off and recrystallized from aqeuous ethanol to give
a solid product (0.97 g; 40%) that was found to be identi-
cal in all aspects (mp, mixed mp, and IR data) to authen-
tic sample of 3a obtained by method A.
Synthesis of 8-[(4-Methoxyphenyl)diazenyl]-7,9-
diphenylpyrido[3’,2’:4,5]thieno[3,2-c]pyridazin-4(3H)-one (4)
A sample of sodium nitrite (0.005 mol) dissolved in water
(5 ml) was added dropwise with stirring to an ice-cold solu-
tion (0-5 ºC) of 3b (0.003 mol) in acetic acid (30 ml). After
the completion of addition, the reaction mixture was sti-
rred for 1 h and then left  overnight at room temperature.
The solid obtained was isolated by filtration, dried and
recrystallized from EtOH to give the corresponding tricy-
clic product 4 (0.72 g; 49%). Mp 161-162 ºC; IR (ν/cm–1) =
3065 (CH aromatic), 1704 (C=O ring), 1622 (C=N); 1H NMR
δH = 3.80 (s, 3H, OCH3), 4.88 (s, 2H, pyridazinone-CH2), 7.27-
7.85 (m, 14H, 2C6H5, C6H4); MS: m/z (%) = 489 (M
+, 22%);
C28H19N5O2S (489.548): Calcd: C, 68.70; H, 3.91; N, 14.31; S,
6.55; Found: C, 68.53; H, 3.82; N, 14.13; S, 6.40.
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Figure 3. Variation of the magnitude and direction of the
dipole moment of thieno[2,3-b]pyridine derivatives. For the
sake of clarity, the dipole moment vectors were translated
to the centre of mass of the thieno[2,3-b]pyridine moiety.
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General Procedure for the Synthesis of 5-(Aryldiazenyl)-
2-acetyl-4,6-diphenyl-3-(1H-pyrrol-1-yl)thieno[2,3-b]
pyridines 5a,b
A mixture of either enaminoketone 3a or 3b (0.005 mol) and
dimethoxytetrahydrofuran (0.005 mol), in glacial acetic acid
(30 ml), was boiled under reflux for 1 h. The solvent was
distilled off under reduced pressure and the residual pro-
ducts were triturated with water, whereupon the solid that
formed, in each case, was collected by filtration and recrys-
tallized from the appropriate solvent to give the corres-
ponding pyrrol-1-yl derivatives 5a (1.28 g; 48%) and 5b
(1.45 g; 55%), respectively. 
2-Acetyl-5-[(4-chlorophenyl)diazenyl]-4,6-diphenyl-3-
(1H-pyrrol-1-yl)thieno[2,3-b]pyridine (5a)
Mp 148-149 ºC (MeOH); IR (ν/cm–1) = 3042 (CH aromatic),
1681 (C=O ketone), 1617 (C=N); 1H NMR δH = 2.57 (s, 3H,
COCH3), 6.29 (m, 2H, 3’-H, 4’-H pyrrole), 7.10 (m, 2H, 2’-H,
5’-H pyrrole), 7.47-7.92 (m, 14H, 2C6H5, C6H4); 
13C NMR δ =
26.9 (CH3), 107.8, 119.0 (pyrrole-C), 125.1, 125.6, 126.3,
126.8, 127.1, 127.6, 128.2, 128.6, 129.0, 129.3, 130.1, 133.9,
138.1, 139.4, 142.9, 143.3, 144.7, 150.7, 158.5 (aromatic-
C), 191.2 (C=O); C31H21ClN4OS (533.043): Calcd: C, 69.85;
H, 3.97; Cl, 6.65; N, 10.51; S, 6.02; Found: C, 69.57; H, 3.85;
Cl, 6.51; N, 10.39; S, 5.88.
2-Acetyl-5-[(4-methoxyphenyl)diazenyl]-4,6-diphenyl-3-
(1H-pyrrol-1-yl)thieno[2,3-b]pyridine (5b)
Mp 127-128 ºC (MeOH/H2O); IR (ν/cm
–1) = 3037 (CH aro-
matic), 1681 (C=O ketone), 1613 (C=N); 1H NMR δH = 2.44
(s, 3H, COCH3), 3.86 (s, 3H, OCH3), 6.37 (m, 2H, 3’-H, 4’-H
pyrrole), 7.02 (m, 2H, 2’-H, 5’-H pyrrole), 7.33-7.79 (m, 14H,
2C6H5, C6H4); MS: m/z (%) = 528 (M
+, 18%); C32H24N4O2S
(528.624): Calcd: C, 72.71; H, 4.58; N, 10.60; S, 6.07; Found:
C, 72.51; H, 4.33; N, 10.38; S, 5.90.
Synthesis of 3-(Dimethylamino)-1-{5-[(4-methoxyphenyl)
diazenyl]-4,6-diphenyl-3-(1H-pyrrol-1-yl)thieno[2,3-b]
pyridin-2-yl}prop-2-en-1-one (6)
A mixture of 5b (0.005 mol) and DMFDMA (0.006 mol) was
refluxed in xylene (30 ml) for 12 h. The solvent was remo-
ved by evaporation under vacuo. The solid formed was fil-
tered off, dried and recrystallized from EtOH to give the
enaminone 6 (1.52 g; 52%). Mp 172 ºC; IR (ν/cm–1) = 3050
(CH aromatic), 1652 (C=O ketone), 1616 (C=N); 1H NMR
δH = 2.98 (s, 6H, 2NCH3), 3.96 (s, 3H, OCH3), 5.75 (d, 1H, J
= 14 Hz, vinyl H-2), 6.22 (m, 2H, 3’-H, 4’-H pyrrole), 6.93 (m,
2H, 2’-H, 5’-H pyrrole), 7.20-7.71 (m, 14H, 2C6H5, C6H4), 8.40
(d, 1H, J = 14 Hz, vinyl H-3); 13C NMR δC = 45.2 [N(CH3)2],
56.3 (OCH3), 93.0 (olefinic-C=C-N), 108.2, 118.7 (pyrrole-
C), 113.5, 120.7, 125.7, 126.9, 127.0, 127.5, 128.3, 128.7,
129.0, 129.4, 129.9, 137.6, 139.8, 142.3, 143.6, 144.5, 149.9,
154.7 (olefinic-C=C-N), 159.6, 164.2 (C-OCH3), 180.8 (C=O);
MS: m/z (%) = 583 (M+, 21%); C35H29N5O2S (583.702): Calcd:
C, 72.02; H, 5.01; N, 12.00; S, 5.49; Found: C, 71.76; H, 4.84;
N, 11.79; S, 5.39.
Synthesis of 2-(Isoxazol-5-yl)-5-[(4-methoxyphenyl)
diazenyl]-4,6-diphenyl-3-(1H-pyrrol-1-yl)thieno[2,3-b]
pyridine (10a)
Compound 6 (0.005 mol) was mixed with hydroxylamine
hydrochloride (0.006 mol), in ethanol (30 ml) containing
anhydrous sodium acetate (0.5 g). The mixture was hea-
ted at reflux for 6 h, allowed to cool at room temperature
and then diluted with cold water. The solid that separated
was filtered off, washed with water, dried and recrystalli-
zed from 1,4-dioxane to give 10a (1.61 g; 58%). Mp 197-
199 ºC; IR (ν/cm–1) = 3063 (CH aromatic), 1614 (C=N); 1H
NMR δH = 3.96 (s, 3H, OCH3), 6.47 (m, 2H, 3’-H, 4’-H pyrro-
le), 6.94 (m, 2H, 2’-H, 5’-H pyrrole), 6.98 (d, 1H, J = 2 Hz, 4-
H isoxazole), 7.32-8.00 (m, 14H, 2C6H5, C6H4), 8.39 (d, 1H,
J = 2 Hz, 3-H isoxazole); C33H23N5O2S (553.633): Calcd: C,
71.59; H, 4.19; N, 12.65; S, 5.79; Found: C, 71.36; H, 4.04;
N, 12.47; S, 5.81. 
General Procedure for the Synthesis of 2-(1-Substituted-
1H-pyrazol-5-yl)-5-[(4-methoxyphenyl)diazenyl]-4,6-
diphenyl-3-(1H-pyrrol-1-yl)thieno[2,3-b]pyridines 10b,c
To a solution of enaminone 6 (0.005 mol), in absolute etha-
nol (30 ml), either hydrazine hydrate (1 ml, 0.02 mol) or
phenylhydrazine (0.75 ml, 0.0076 mol) were added. The
reaction mixture was heated at reflux for 4 h, left to cool
at room temperature and then poured over cold water. The
solid products that separated were isolated by filtration,
washed with ethanol, dried and recrystallized from the pro-
per solvents to give 10b (1.38 g; 44%) and 10c (1.41 g;
51%), respectively.  
5-[(4-Methoxyphenyl)diazenyl]-4,6-diphenyl-2-(1-phenyl-
1H-pyrazol-5-yl)-3-(1H-pyrrol-1-yl)thieno[2,3-b]pyridine
(10b)
Mp 205-206 ºC (EtOH/H2O); IR (ν/cm
–1) = 3056 (CH aroma-
tic), 1620 (C=N); 1H NMR δH = 3.77 (s, 3H, OCH3), 6.40 (m,
2H, 3’-H, 4’-H pyrrole), 6.79 (d, 1H, J = 2 Hz, 4-H pyrazo-
le), 7.03 (m, 2H, 2’-H, 5’-H pyrrole), 7.28-7.82 (m, 19H, 3C6H5,
C6H4), 7.85 (d, 1H, J = 2 Hz, 3-H pyrazole); MS: m/z (%) =
628 (M+, 25%); C39H28N6OS (628.744): Calcd: C, 74.50;
H, 4.49; N, 13.37; S, 5.10; Found: C, 74.36; H, 4.26; N, 13.11;
S, 4.88.
5-[(4-Methoxyphenyl)diazenyl]-4,6-diphenyl-2-
(1H-pyrazol-5-yl)-3-(1H-pyrrol-1-yl)thieno[2,3-b]pyridine
(10c)
Mp 183-185 ºC (AcOH); IR (ν/cm–1) = 3241 (NH), 3045 (CH
aromatic), 1612 (C=N); 1H NMR δH = 3.89 (s, 3H, OCH3), 5.90
(d, 1H, J = 2 Hz, 4-H pyrazole), 6.28 (m, 2H, 3’-H, 4’-H pyrro-
le), 7.12 (m, 2H, 2’-H, 5’-H pyrrole), 7.21-7.97 (m, 14H, 2C6H5,
C6H4), 8.22 (d, 1H, J = 2 Hz, 3-H pyrazole), 13.06 (s, br, 1H,
NH, D2O-exchangeable); C33H24N6OS (552.648): Calcd: C,
71.72; H, 4.38; N, 15.21; S, 5.80; Found: C, 71.61; H, 4.21;
N, 14.96; S, 5.59.
Synthesis of 1-{5-[(4-Methoxyphenyl)diazenyl]-4,6-
diphenyl-3-(1H-pyrrol-1-yl)thieno[2,3-b]pyridin-2-yl}
ethanone oxime (12a)
A mixture of 5b (0.002 mol) and hydroxylamine hydrochlo-
ride (0.0024 mol), in pyridine (20 ml), was refluxed for 6 h.
The solvent was removed and the residue was diluted with
ethanol, neutralized with dilute hydrochloric acid, and when
cooled, a solid was deposited. This solid was collected by
filtration and recrystallized from 1,4-dioxane to give 12a
(0.66 g; 61%). Mp 141-142 ºC; IR (ν/cm–1) = 3455 (OH), 3047
(CH aromatic), 1614 (C=N); 1H NMR δH = 2.57 (s, 3H, CH3),
3.75 (s, 3H, OCH3), 6.38 (m, 2H, 3’-H, 4’-H pyrrole), 6.94 (m,
2H, 2’-H, 5’-H pyrrole), 7.14-7.85 (m, 14H, 2C6H5, C6H4), 11.20
(s, 1H, OH, D2O-exchangeable); C32H25N5O2S (543.638): Calcd:
C, 70.70; H, 4.64; N, 12.88; S, 5.90; Found: C, 70.44; H, 4.42;
N, 12.73; S, 5.75.
Synthesis of 5-[(4-Methoxyphenyl)diazenyl]-4,6-diphenyl-
2-[1-(2-phenylhydrazono)ethyl]-3-(1H-pyrrol-1-yl)
thieno[2,3-b]pyridine (12b)
A mixture of the acetyl derivative 5b (0.002 mol) and
phenylhydrazine (0.0024 mol), in absolute ethanol (30 ml)
AFINIDAD LXV, 533, Enero-Febrero 2008 69
TRIPA 533  13/5/08  10:59  Página 69
containing a few drops of acetic acid, was refluxed for
6 h. The reaction mixture was then cooled and poured onto
cold water. The solid product obtained was collected by
filtration and recrystallized from EtOH/H2O (1:1) to give 12b
(0.80 g; 65%). Mp 98 ºC; IR (ν/cm–1) = 3210 (NH), 3042 (CH
aromatic), 1615 (C=N); 1H NMR δH = 2.20 (s, 3H, CH3), 3.91
(s, 3H, OCH3), 6.26 (m, 2H, 3’-H, 4’-H pyrrole), 7.16 (m, 2H,
2’-H, 5’-H pyrrole), 7.20-8.09 (m, 19H, 3C6H5, C6H4), 10.82
(s, 1H, NH, D2O-exchangeable); C38H30N6OS (618.749): Calcd:
C, 73.76; H, 4.89; N, 13.58; S, 5.18; Found: C, 73.60; H, 4.68;
N, 13.44; S, 4.97.
General Procedure for the Synthesis of 2-Heterocyclyl-
5-[(4-methoxyphenyl)diazenyl]-4,6-diphenyl-3-
(1H-pyrrol-1-yl)thieno[2,3-b]pyridines 11a,b
A mixture of either 12a or 12b (0.0025 mol) and DMFDMA
(0.003 mol) was refluxed in xylene (20 ml) for 18 h. The solid
obtained on evaporating excess solvent under vacuo was
collected by filtration and recrystallized from the appro-
priate solvents to give 11a (0.97 g; 70%) and 11b (0.99 g;
63%), respectively. 
3-{5-[(4-Methoxyphenyl)diazenyl]-4,6-diphenyl-3-
(1H-pyrrol-1-yl)thieno[2,3-b]pyridin-2-yl}isoxazole (11a)
Mp 230-232 ºC (1,4-dioxane); IR (ν/cm–1) = 3049 (CH aro-
matic), 1616 (C=N); 1H NMR δH = 3.81 (s, 3H, OCH3), 6.23
(m, 2H, 3’-H, 4’-H pyrrole), 6.99 (m, 2H, 2’-H, 5’-H pyrrole),
7.18 (d, 1H, J = 3 Hz, 4-H isoxazole), 7.24-7.95 (m, 14H,
2C6H5, C6H4), 8.92 (d, 1H, J = 3 Hz, 5-H isoxazole); 
13C NMR
δC = 55.9 (OCH3), 104.2 (isoxazole-C4), 108.5, 118.9 (pyrro-
le-C), 114.0, 121.2, 124.3, 126.7, 127.1, 127.6, 128.3, 128.6,
129.3, 129.7, 130.1, 137.5, 138.3, 140.1, 142.9, 144.2, 149.7,
150.1 (aromatic-C), 150.5 (isoxazole-C3), 159.1 (isoxazole-
C5), 163.9 (C-OCH3); C33H23N5O2S (553.633): Calcd: C, 71.59;
H, 4.19; N, 12.65; S, 5.79; Found: C, 71.44; H, 3.98; N, 12.53;
S, 5.58. 
5-[(4-Methoxyphenyl)diazenyl]-4,6-diphenyl-2-(1-phenyl-
1H-pyrazol-3-yl)-3-(1H-pyrrol-1-yl)thieno[2,3-b]pyridine
(11b)
Mp 251-253 ºC (DMF); IR (ν/cm–1) = 3060 (CH aromatic),
1619 (C=N); 1H NMR δH = 3.84 (s, 3H, OCH3), 6.31 (m, 2H,
3’-H, 4’-H pyrrole), 6.81 (d, 1H, J = 3 Hz, 4-H pyrazole), 7.17
(m, 2H, 2’-H, 5’-H pyrrole), 7.23-7.88 (m, 19H, 3C6H5, C6H4),
7.93 (d, 1H, J = 3 Hz, 5-H pyrazole); C39H28N6OS (628.744):
Calcd: C, 74.50; H, 4.49; N, 13.37; S, 5.10; Found: C, 74.25;
H, 4.32; N, 13.28; S, 4.91.
General Procedure for the Synthesis of 2-(2-Arylhydrazono)-
3-{5-[(4-methoxyphenyl)diazenyl]-4,6-diphenyl-3-(1H-pyrrol-
1-yl)thieno[2,3-b]pyridin-2-yl}-3-oxopropanals 14a,b
A solution of enaminone 6 (0.005 mol), in ethanol (50 ml)
containing sodium hydroxide (0.8 g), was refluxed for 15
min and the solution was then cooled to 0-5 ºC with sti-
rring. The reaction mixture was then treated gradually with
a cold solution of the appropriate aryldiazonium chloride
salt (0.005 mol) [prepared by adding a cold solution (0-5 ºC)
of sodium nitrite (0.005 mol, 0.35 g into 5 ml water) to a
cold solution (0-5 ºC) of the corresponding arylamine
hydrochloride (0.005 mol of arylamine in 2.5 ml concen-
trated hydrochloric acid) with continuous stirring at 0-5 ºC].
The mixture was then stirred at room temperature for an
additional 2 h. The precipitated product, in each case, sepa-
rated upon dilution with cold water (30 ml) was filtered off,
washed with water several times, dried, and recrystallized
from EtOH to give 14a (1.69 g; 50%) and 14b (1.46 g; 42%),
respectively.
3-{5-[(4-Methoxyphenyl)diazenyl]-4,6-diphenyl-3-(1H-
pyrrol-1-yl)thieno[2,3-b]pyridin-2-yl}-3-oxo-2-(2-p-tolylhy-
drazono)propanal (14a)
Mp 155-156 ºC; IR (ν/cm–1) = 3432 (NH), 3041 (CH aroma-
tic), 1662 (C=O aldehyde), 1637 (C=O ketone), 1615 (C=N);
1H NMR δH = 2.28 (s, 3H, CH3), 3.79 (s, 3H, OCH3), 6.40 (m,
2H, 3’-H, 4’-H pyrrole), 7.07 (m, 2H, 2’-H, 5’-H pyrrole), 7.25-
7.99 (m, 18H, 2C6H5, 2C6H4), 10.02 (s, 1H, CHO), 14.20 (s,
br, 1H, NH hydrazone, D2O-exchangeable); MS: m/z (%) =
674 (M+, 16%); C40H30N6O3S (674.770): Calcd: C, 71.20; H,
4.48; N, 12.45; S, 4.75; Found: C, 70.93; H, 4.33; N, 12.24;
S, 4.60.
2-[2-(4-Chlorophenyl)hydrazono]-3-{5-[(4-methoxyphenyl)
diazenyl]-4,6-diphenyl-3-(1H-pyrrol-1-yl)thieno[2,3-b]pyridin-
2-yl}-3-oxopropanal (14b)
Mp 243-245 ºC; IR (ν/cm–1) = 3441 (NH), 3033 (CH aroma-
tic), 1667 (C=O aldehyde), 1640 (C=O ketone), 1618 (C=N);
1H NMR δH = 3.90 (s, 3H, OCH3), 6.26 (m, 2H, 3’-H, 4’-H pyrro-
le), 7.24 (m, 2H, 2’-H, 5’-H pyrrole), 7.30-8.02 (m, 18H, 2C6H5,
2C6H4), 10.08 (s, 1H, CHO), 13.83 (s, br, 1H, NH hydrazone,
D2O-exchangeable); C39H27ClN6O3S (695.188): Calcd: C, 67.38;
H, 3.91; Cl, 5.10; N, 12.09; S, 4.61; Found: C, 67.24; H, 3.72;
Cl, 4.94; N, 11.86; S, 4.55.
Synthesis of 3-{5-[(4-Methoxyphenyl)diazenyl]-4,6-diphenyl-
3-(1H-pyrrol-1-yl)thieno[2,3-b]pyridine-2-carbonyl}-1,5-
dip-tolylformazan (16)
Method A
To a stirred solution of hydrazonal 14a (0.002 mol) at 0-5 ºC,
in ethanol (30 ml) containing sodium hydroxide (0.3 g), p-
toluenediazonium chloride salt (0.002 mol) [prepared from
the corresponding p-toluidine (0.002 mol) and the appro-
priate quantities of concentrated hydrochloric acid and
sodium nitrite] was added dropwise while cooling at 0-5 ºC
and stirring. After addition of the diazonium salt, the reac-
tion mixture was then stirred at room temperature for an
additional 2 h. The precipitated product, separated upon
dilution with cold water (30 ml), was filtered off, washed
with water several times, dried, and recrystallized from
DMF/EtOH (1:2) to give the corresponding formazan 16 (0.90
g; 59%). Mp 266-268 ºC; IR (ν/cm–1) = 3390 (NH), 3052 (CH
aromatic), 1651 (C=O with H-bonding between O and NH),
1616 (C=N); 1H NMR δH = 2.27 (s, 6H, 2CH3), 3.94 (s, 3H,
OCH3), 6.33 (m, 2H, 3’-H, 4’-H pyrrole), 6.90 (m, 2H, 2’-H, 5’-
H pyrrole), 6.95-8.11 (m, 22H, 2C6H5, 3C6H4), 12.15 (s, br, 1H,
NH hydrazone, D2O-exchangeable); MS: m/z (%) = 764 (M
+,
23%); C46H36N8O2S (764.895): Calcd: C, 72.23; H, 4.74; N,
14.65; S, 4.19; Found: C, 71.97; H, 4.60; N, 14.46; S, 4.01.
Method B
A cold solution (0-5 ºC) of p-toluenediazonium chloride salt
(0.005 mol) was prepared by addition of a cold solution (0-
5 ºC) of sodium nitrite (0.005 mol) in water (5 ml) to a solu-
tion of p-toluidine (0.005 mol) in concentrated hydrochlo-
ric acid (2.5 ml) at 0-5 ºC with vigorous stirring. The resulting
solution of the diazonium salt was added dropwise with
continuous stirring to a cold solution (0-5 ºC) of enamino-
ne 6 (0.0025 mol) in DMF (30 ml) containing sodium hydro-
xide (0.8 g). The mixture was kept at room temperature for
2 h under stirring. The precipitate formed was washed with
water, collected by filtration, and recrystallized from
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DMF/EtOH (1:2) to give a solid product (1.17 g; 61%) iden-
tical to that described in method A.
Synthesis of 3-{5-[(4-Methoxyphenyl)diazenyl]-4,6-diphenyl-
3-(1H-pyrrol-1-yl)thieno[2,3-b]pyridine-2-carbonyl}-6-
methylcinnoline (18)
A sample of hydrazonal 14a (1 g), in concentrated sulfuric
acid (15 ml), was heated at reflux for 15 min and then allo-
wed to cool. Under stirring, the reaction mixture was pou-
red over iced water. The separated solid product was collec-
ted by filtration, washed with water, dried and recrystallized
from EtOH to give the cinnoline derivative 18 (0.55 g; 57%).
Mp 275-276 ºC; IR (ν/cm–1) = 3058 (CH aromatic), 1662 (C=O
ketone), 1619 (C=N); 1H NMR δH = 2.30 (s, 3H, CH3), 3.77 (s,
3H, OCH3), 6.29 (m, 2H, 3’-H, 4’-H pyrrole), 7.01 (m, 2H, 2’-
H, 5’-H pyrrole), 7.26-8.31 (m, 17H, 2C6H5, C6H4, 5-H, 7-H,
8-H cinnoline), 8.92 (s, 1H, 4-H cinnoline); 13C NMR δC = 22.8
(CH3), 55.6 (OCH3), 108.0, 119.2 (pyrrole-C), 113.8, 120.9,
122.1, 124.5, 125.7, 126.8, 127.0, 127.3, 127.9, 128.2, 128.5,
128.9, 129.5, 130.2, 130.7, 133.0, 137.3, 138.7, 140.8, 142.5,
143.3, 144.7, 147.2, 149.9, 154.5, 160.1 (aromatic-C), 163.5
(C-OCH3), 185.2 (C=O); MS: m/z (%) = 656 (M
+, 19%);
C40H28N6O2S (656.754): Calcd: C, 73.15; H, 4.30; N, 12.80; S,
4.88; Found: C, 72.92; H, 4.21; N, 12.58; S, 4.72.
Energetics
Molecular orbital geometry optimizations were performed
using the semi-empirical Austin Model (AM1) Hamiltonian
at a restricted Hartree-Fock (RHF) self-consistent field level
within the GAMESS package(44). A gradient tolerance of 10–4
Hartree Å–1 was used throughout. The rotational energy pro-
files were obtained by constraining the C1-C2-N=N dihe-
dral to discreet values while the rest of the degrees of fre-
edom were subjected to full geometry optimization. 
The electrostatic component of the solvation free energy
(∆Asolv) was calculated by solving the Poisson-Boltzmann
(PB) equation(45) for the geometry optimized structures using
the APBS package(46). The ∆Asolv values were obtained from
the difference between the electrostatic potential compu-
ted in bulk solvent (salt concentration = 0.15 M, relative
dielectric permitivity = 80) and the electrostatic potential
calculated in vacuum (salt concentration = 0.0 M, relative
dielectric permitivity = 1.0) at 310 K.  In order to increase
the accurecy of the calculations, the focusing technique(47)
was used where three focussing stages were carried out.
A final grid spacing of 0.3 Å  was used and the relative die-
lectric permitivity within the structures  was  set to 1. The
solute-solvent boundary was constructed from the solvent
accessible surface using a solvent probe radius of 1.4 Å.
BIBLIOGRAPHY
(1). Laufer, S.A.; Wagner, G.K.: J. Med. Chem., 45, 2733-
2740 (2002). 
(2). Springer, D.M.; Luh, B.-Y.; Bronson, J.J.: Bioorg. Med.
Chem. Lett., 11, 797-801 (2001).
(3). Zubarev, A.A.; Zav’yalova, V.K.; Litvinov, V.P.: Doklady
Chemistry, 388, 6-8 (2003).
(4). Sakurai, H.; Sano, H.; Takino, T.; Yasui, H.: Chem. Lett.,
913-914 (1999).
(5). Shestopalov, A.M.; Nikishin, K.G.; Gromova, A.V.;
Rodinovskaya, L.A.: Russ. Chem. Bull., Int. Ed., 52, 2203-
2206 (2003). 
(6). Litvinov, V.P.; Rodinovskaya, L.A.; Sharanin, Yu.A.;
Shestopalov, A.M.; Senning, A.: Sulfur Rep., 13, 1-155 (1992). 
(7). Litvinov, V.P.: Russ. Chem. Rev., 68, 737-763 (1999).
(8). Shraideh, Z.; Sallal, A.-K.: Biomed. Lett., 54, 233-237
(1997).
(9). Bompart, J.; Giral, L.; Malicorne, G.; Puygrenier, M.: Eur.
J. Med. Chem., 22, 139-145 (1987).
(10). Munchhof, M.J.; Sobolov-Jaynes, S.B.; Marx, M.A.: U.
S., 6492383 (2002); C.A. 138, 24721 (2003). 
(11). Nakanishi, M.; Imamura, H.; Maruyama, Y.; Hoshino, H.:
Yakugaku zasshi: J. Pharmaceutical Soc. Jpn., 90, 272-276
(1970).
(12). Sohda, T.; Makino, H.; Baba, A.: PCT Int. Appl. WO, 96,
14, 319 (1996);  C.A. 125, 114583 (1996). 
(13). Vieweg, H.; Leistner, S.; Prantz, J.; Böhm, N.; Wagner,
G.: Pharmazie, 47, 841-845 (1992).
(14). Ono, N.; Muratani, E.; Ogawa, T.: J. Heterocyclic Chem.,
28, 2053-2055 (1991).
(15). Nishiwaki, N.; Nakanishi, M.; Hida, T.; Miwa, Y.; Tamura,
M.; Hori, K.; Tohda, Y.; Ariga, M.: J. Org. Chem., 66, 7535-
7538 (2001).
(16). Koyama, M.; Ezaki, N.; Tsuruoka, T.; Inouye, S.: J.
Antibiotics, 36, 1483-1489 (1983).
(17). Koyama, M.; Ohtani, N.; Kai, F.; Moriguchi, I.; Inouye,
S.: J. Med. Chem., 30, 552-562 (1987).
(18). Khanna, I.K.; Weier, R.M.; Yu, Y.; Collins, P.W.; Miyashiro,
J.M.; Koboldt, C.M.; Veenhuizen, A.W.; Currie, J.L.; Seibert,
K.; Isakson, P.C.: J. Med. Chem., 40, 1619-1633 (1997).
(19). Wilkerson, W.W.; Copeland, R.A.; Covington, M.;
Trzaskos, J.M.: J. Med. Chem., 38, 3895-3901 (1995).
(20). Wilkerson, W.W.; Galbraith, W.; Gans-Brangs, K.; Grubb,
M.; Hewes, W.E.; Jaffee, B.; Kenney, J.P.; Kerr, J.; Wong,
N.: J. Med. Chem., 37, 988-998 (1994).
(21). Roth, B.D.: Prog. Med. Chem., 40, 1-22 (2002).
(22). Fürstner, A.: Angew. Chem., Int. Ed., 42, 3582-3603
(2003).
(23). Kral, V.; Davis, J.; Andrievsky, A.; Kralova, J.; Synytsya,
A.; Pouckova, P.; Sessler, J.L.: J. Med. Chem., 45, 1075-
1078 (2002).
(24). Filichev, V.V.; Gaber, H.; Olsen, T.R.; Jørgensen, P.T.;
Jessen, C.H.; Pedersen, E.B.: Eur. J. Med. Chem., 3960-
3968 (2006).   
(25). Anwar, H.F.; Metwally, N.H.; Gaber, H.; Elnagdi, M.H.:
J. Chem. Res., 29-31 (2005). 
(26). Ghozlan, S.A.S.; Abdelhamid, I.A.; Gaber, H.; Elnagdi,
M.H.: J. Chem. Res., 789-793 (2004).  
(27). Erian, A.W.; Sherif, S.M.; Gaber, H.M.: Molecules, 8, 793-
865 (2003).
(28). Gaber, H.M.; Elgemeie, G.E.H.; Ouf, S.A.; Sherif, S.M.:
Heteroat. Chem., 16, 298-307 (2005).
(29). Elgemeie, G.E.H.; Alnaimi, I.S.; Alarab, H.F.: Heterocycles,
34, 1721-1728 (1992).
(30). Cugnon de Sevricourt, M.; El-Khashef, H.; Rault, S.;
Robba, M.: Synthesis, 710-711 (1981).
(31). Kambulov, E.Yu.; Vasilin, V.K.; Kaigorodova, E.A.;
Konyushkin, L.D.; Krapivin, G.D.: Chem. Heterocycl.
Compd., 39, 255-262 (2003).
(32). Moran, D.; Sukcharoenphon, K.; Puchta, R.; Schaefer,
H.F.; Schleyer, P.V.R.; Hoff, C.D.: J. Org. Chem., 67, 9061-
9069 (2002).
(33). Zubarev, A.A.; Zav’yalova, V.K.; Litvinov, V.P.: Russ.
Chem. Bull., Int. Ed., 52, 978-983 (2003).
(34). Elgemeie, G.E.H.; Attia, A.M.E.; Fathy, N.M.: J. Chem.
Res. (S), 112-113 (1997).
(35). Ghozlan, S.A.S.; Abdelhamid, I.A.; Gaber, H.M.; Elnagdi,
M.H.: J. Heterocyclic Chem., 42, 1185-1189 (2005).  
(36). Heinisch, G.; Frank, H.: «Pharmacologically Active
Pyridazine Derivatives, in: Progress in Medicinal Chemistry»
(Eds.: Ellis, G. P.; Luscombe, D. K.), Elsevier, Amsterdam,
Part 1, Vol. 27, pp. 1-49 (1990) and ibid. (Eds.: Ellis, G. P.;
West, G. B.), Elsevier, Amsterdam, Part 2, Vol. 29, pp. 141-
183 (1992).
AFINIDAD LXV, 533, Enero-Febrero 2008 71
TRIPA 533  13/5/08  10:59  Página 71
(37). Coates, W.J.: «Pyridazines and their Benzo Derivatives»,
in: Comprehensive Heterocyclic Chemistry II, (Eds.:
Katritzky, A. R.; Rees, C. W.; Scriven, E. F. V.), Pergamon,
London, Vol. 6, pp. 87-89 (1996).
(38). Melikian, A.; Schlewer, G.; Chambon, J.P.; Wermuth;
C.G.: J. Med. Chem., 35, 4092-4097 (1992).
(39). Dewar, M.J.S.; Zoebisch, E.G.; Healy, E.F.; Stewart,
J.J.P.: J. Am. Chem.  Soc., 107, 3902-3909 (1985).
(40). Dewar, M.J.S.; Yuan, Y.C.: Inorg. Chem., 29, 3881-3890
(1990).
(41). El Hassan, M.E.; Calladine, C.R.: Philos. Trans. R. Soc.
London, 355, 43-100 (1997).
(42). Hunter, C.A.; Lu, X.J.: J. Mol. Biol., 265, 603-619 (1997).
(43). Holst, M.J.; Saied, F.: J. Comput. Chem., 16, 337-364
(1995).
(44). Schmidt, M.W.; Baldridge, K.K.; Boatz, J.A.; Elbert, S.T.;
Gordon, M.S.; Jensen, J.H.; Koseki, S.; Matsunaga, N.;
Nguyen, K.A.; Su, S. et al.: J. Comput. Chem., 14, 1347-
1363 (1993).
(45). Roux, B.; Simonson, T.: Biophys. Chem., 78, 1-20 (1999).
(46). Baker, N.A.; Sept, D.; Joseph, S.; Holst, M.J.;
McCammon, J.A.: PNAS, 98, 10037-10041 (2001).
(47). Gilson, M.K.; Honig, B.: Proteins: Structure, Function,
and Genetics, 4, 7-18 (1988).
72 AFINIDAD LXV, 533, Enero-Febrero 2008
TRIPA 533  13/5/08  10:59  Página 72
